Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Alzheimer's disease (AD)

Glycogen dependent kinase 3 (GSK3)

Mouse studies suggest inhibiting GSK3 could help to treat AD. In a mouse model of aggressive AD, animals showed hyperactive GSK3 and developed massive cerebral b-amyloid (Ab) loads, memory deficits and neuronal loss. Nasal delivery of the GSK3 inhibitor L803-mt decreased Ab deposits and increased cognitive function compared with no treatment. Next steps include completing preclinical safety and toxicity studies.

SciBX 5(48); doi:10.1038/scibx.2012.1262
Published online Dec. 13, 2012

Patented by Ramot at Tel Aviv University; available for licensing

Avrahami, L. et al. J. Biol. Chem.; published online Nov. 15, 2012;
doi:10.1074/jbc.M112.409250
Contact: Hagit Eldar-Finkelman, Tel Aviv University, Tel Aviv, Israel
e-mail:
heldar@post.tau.ac.il

Contact: Dan Frenkel, same affiliation as above
e-mail:
dannyf34@gmail.com